Latest Therapeutics News

Page 38 of 49
AVITA Medical reported a robust 67% increase in first quarter 2025 revenue, driven by new product launches and a strategic commercial overhaul, while reaffirming its full-year growth and profitability targets.
Ada Torres
Ada Torres
9 May 2025
Algorae Pharmaceuticals has partnered with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its oncology pipeline development.
Ada Torres
Ada Torres
8 May 2025
Nyrada’s experimental drug NYR-BI03 shows promising cardioprotective and anti-arrhythmic effects in animal models, reinforcing its potential as a treatment for acute myocardial infarction.
Ada Torres
Ada Torres
8 May 2025
LTR Pharma has partnered with Strategic Drug Solutions to co-develop OROFLOW®, a novel intranasal spray aimed at providing fast symptom relief for Oesophageal Motility Disorders, tapping into a growing $4.5 billion global market.
Ada Torres
Ada Torres
8 May 2025
Alterity Therapeutics is set to present compelling Phase 2 clinical trial results for ATH434 at the 2025 International Multiple System Atrophy Congress, highlighting slowed disease progression and biomarker engagement in MSA patients.
Ada Torres
Ada Torres
7 May 2025
Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.
Ada Torres
Ada Torres
6 May 2025
Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.
Ada Torres
Ada Torres
6 May 2025
Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.
Ada Torres
Ada Torres
6 May 2025
Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.
Ada Torres
Ada Torres
5 May 2025
AdAlta Limited has announced a pro rata renounceable rights offer to raise approximately $1.29 million, aiming to fund its strategic pivot towards licensing CAR-T cell therapies through its subsidiary AdCella. The offer includes new shares and options, underpinned by key insiders and an underwriting agreement.
Ada Torres
Ada Torres
5 May 2025
Anagenics Ltd has reported a significant earnings turnaround in 3Q25 following a strategic business restructure, alongside securing a multi-year royalty agreement worth $4.4 million with York Street Brands.
Victor Sage
Victor Sage
5 May 2025
Neurizon Therapeutics has announced the successful completion of its Open-Label Extension study for NUZ-001 in ALS, revealing significant survival benefits and strong tolerability. The company is on track to release top-line results in Q3 2025 and advance to a pivotal Phase 2/3 trial.
Ada Torres
Ada Torres
5 May 2025